The necessity of adjuvant chemotherapy in young patients with T1N0M0 breast cancer: a population-based study.

IF 3.2 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Clinical and Experimental Medicine Pub Date : 2025-03-20 DOI:10.1007/s10238-025-01621-2
Sheng Chen, Shujie Chen, Wei Cao, Xiaoyun Zhou, Min Wei, Jie Wang, Li Yang
{"title":"The necessity of adjuvant chemotherapy in young patients with T<sub>1</sub>N<sub>0</sub>M<sub>0</sub> breast cancer: a population-based study.","authors":"Sheng Chen, Shujie Chen, Wei Cao, Xiaoyun Zhou, Min Wei, Jie Wang, Li Yang","doi":"10.1007/s10238-025-01621-2","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapy clearly adversely affects fertility in women of childbearing age. But it is not yet clear whether chemotherapy at the expense of fertility can benefit younger patients with early-stage breast cancer. We conducted a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results database and the Shanghai Jiao Tong University Breast Cancer Data Base spanning from 2010 to 2020 to investigate early-stage breast malignant carcinoma in patients aged between 20 and 39 years. To address covariate imbalance, propensity score matching (PSM) was employed with a ratio of 1:1 and caliper set at 0.02 standard deviation of propensity score. Univariate and multivariate analyses were performed to evaluate the impact of chemotherapy on both breast cancer-specific survival (BCSS) and overall survival (OS). We identified a total of 6265 patients with complete information about breast cancer. Among them, 3855 patients received chemotherapy. Following successful PSM, we obtained a matched cohort comprising 3038 patients where the characteristics between the two groups were balanced except for race. Kaplan-Meier survival analysis revealed no significant differences in BCSS (P = 0.183) and OS (P = 0.295) between the chemotherapy group and no-chemotherapy group. Similarly, in matched dataset. multivariate COX analysis revealed that chemotherapy did not significantly reduce the risk of BCSS (HR 1.332; 95% CI [0.865-2.051], P = 0.193) and OS (HR 1.225; 95% CI [0.818-1.833], P = 0.324). The chemotherapy group did not demonstrate a superior benefit in any of the subgroups when stratified analyses were conducted based on molecular subtype, tumor size, age, and ethnicity. Chemotherapy fails to significantly improve prognostic outcomes in young patients diagnosed with early-stage breast cancer. With the help of genetic testing, these patients can expect further step-down therapy in the future.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"92"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01621-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Chemotherapy clearly adversely affects fertility in women of childbearing age. But it is not yet clear whether chemotherapy at the expense of fertility can benefit younger patients with early-stage breast cancer. We conducted a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results database and the Shanghai Jiao Tong University Breast Cancer Data Base spanning from 2010 to 2020 to investigate early-stage breast malignant carcinoma in patients aged between 20 and 39 years. To address covariate imbalance, propensity score matching (PSM) was employed with a ratio of 1:1 and caliper set at 0.02 standard deviation of propensity score. Univariate and multivariate analyses were performed to evaluate the impact of chemotherapy on both breast cancer-specific survival (BCSS) and overall survival (OS). We identified a total of 6265 patients with complete information about breast cancer. Among them, 3855 patients received chemotherapy. Following successful PSM, we obtained a matched cohort comprising 3038 patients where the characteristics between the two groups were balanced except for race. Kaplan-Meier survival analysis revealed no significant differences in BCSS (P = 0.183) and OS (P = 0.295) between the chemotherapy group and no-chemotherapy group. Similarly, in matched dataset. multivariate COX analysis revealed that chemotherapy did not significantly reduce the risk of BCSS (HR 1.332; 95% CI [0.865-2.051], P = 0.193) and OS (HR 1.225; 95% CI [0.818-1.833], P = 0.324). The chemotherapy group did not demonstrate a superior benefit in any of the subgroups when stratified analyses were conducted based on molecular subtype, tumor size, age, and ethnicity. Chemotherapy fails to significantly improve prognostic outcomes in young patients diagnosed with early-stage breast cancer. With the help of genetic testing, these patients can expect further step-down therapy in the future.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
化疗显然会对育龄妇女的生育能力产生不利影响。但是,以牺牲生育能力为代价的化疗能否使年轻的早期乳腺癌患者获益,目前尚不清楚。我们利用监测、流行病学和终末结果数据库以及上海交通大学乳腺癌数据库,开展了一项回顾性队列研究,时间跨度为2010年至2020年,研究对象为20至39岁的早期乳腺恶性肿瘤患者。为了解决协变量不平衡的问题,采用了倾向得分匹配法(PSM),比例为1:1,卡尺设定为倾向得分的0.02标准差。我们进行了单变量和多变量分析,以评估化疗对乳腺癌特异性生存(BCSS)和总生存(OS)的影响。我们共发现了 6265 名具有完整乳腺癌信息的患者。其中,3855 名患者接受了化疗。经过成功的 PSM,我们获得了由 3038 名患者组成的配对队列,两组患者除种族外,其他特征均保持平衡。Kaplan-Meier 生存分析显示,化疗组和非化疗组的 BCSS(P = 0.183)和 OS(P = 0.295)无显著差异。同样,在匹配数据集中,多变量 COX 分析显示,化疗并未显著降低 BCSS(HR 1.332;95% CI [0.865-2.051],P = 0.193)和 OS(HR 1.225;95% CI [0.818-1.833],P = 0.324)的风险。根据分子亚型、肿瘤大小、年龄和种族进行分层分析时,化疗组在任何亚组中都没有显示出更优越的获益。化疗无法明显改善早期乳腺癌年轻患者的预后。在基因检测的帮助下,这些患者有望在未来接受进一步的减量治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical and Experimental Medicine
Clinical and Experimental Medicine 医学-医学:研究与实验
CiteScore
4.80
自引率
2.20%
发文量
159
审稿时长
2.5 months
期刊介绍: Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.
期刊最新文献
Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission. GDF15 activates human fibroblast MRC5 cells via miR-338/STAT1 in silicosis. Prioritization of prognostic biomarkers regulated by calorie restriction in colon cancer through integrated biosignature analysis. Role of 18F-FDG PET/CT in assessing systemic involvement in ANCA-associated vasculitis. The necessity of adjuvant chemotherapy in young patients with T1N0M0 breast cancer: a population-based study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1